ANRO · Alto Neuroscience, Inc.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from the Phase 2 proof-of-concept study are expected following completion of dosing and data analysis and are anticipated to guide future development decisions for ALTO-101. Cognitive impairment represents a core, persistent feature of schizophrenia affecting nearly all patients and is a major driver of long-term functional disability, for which there are currently no approved pharmacologic treatments. Alto met its enrollment goal for the Phase 2 proof-of-concept trial (NCT06502964) with 83 CIAS patients enrolled across 13 clinical sites in

– The review provides strong scientific rationale to support Alto’s drug development approach leveraging its Precision Psychiatry Platform – Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience’s leadership team, Patricio O’Donnell, M.D., Ph.D, and Amit Etkin, M.D., Ph.D., as well as Husseini Manji, M.D., former global head of therapeutics, neuroscience at Janssen and a member of Alto’s board of directors. The article consolidates extensive clinical and translational evidence demonstrating that disrupted neuroplasticity—spanning synaptic, cellular, and circuit-level dysfunction—is a shared biological driver across

– Issued and pending claims expected to protect ALTO-207 into the mid-2040s – Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects a key aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effects so that patients can achieve the higher dose levels needed to realize the antidepressant benefits of pramipexole. The newly issued patent claims further strengthen the company’s growing intellectual property estate supporting ALTO-207, a differentiated investigational therapy being developed for patients with treatment-resistant depression. The company believes that, together with previously issued patents and pending applications in the U.S. and

– Data presented demonstrate robust validation of Theta ITC as an EEG biomarker of CIAS and support its use as the primary outcome in the ongoing Phase 2 POC study of ALTO-101 – – Detailed analysis of data from the completed ALTO-203 Phase 2 proof-of-concept study demonstrates clear pharmacodynamic effects and suggests utility of ALTO-203 in indications with excessive daytime sleepiness and/or deficits in sustained attention – Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations highlighting new data and analyses supporting the Company’s development programs at the 64th annual meeting of the American College of Neuropsychopharmacology (ACNP) held January 12-15, 2026. “We are pleased to have the opportunity to showcase the breadth and depth of our precision psychiatry platform at ACNP, which is one of the most highly